Sanofi India PAT at Rs. 529.8 cr in Q3CY21
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
Cipla has reported consolidated financial results for the period ended September 30, 2021
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Collaboration designed to bring reproductive health screening capabilities to hospitals and clinics across the country
Through the mission an entire ecosystem for services from treatment to critical research will be created in every corner of the country
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Subscribe To Our Newsletter & Stay Updated